Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Fiona Simpkins, M.D.

Fiona Simpkins, M.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
B.S. (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Simpkins F, Hevia-Perez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levine ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB Slingerland JM: Preclinical efficacy of combined MEK+SRC inhibition: MEK inhibitor reverses resistance to SRC inhibitor therapy in ovarian cancer cells. Published as abstract for the AACR meeting. Proceed of Advances in Ovarian Cancer Rsrch Page: 138, Sep 2013.

Simpkins F, Garcia-Sota, A, Slingerland J: New insights to hormonal therapies for ovarian cancer. Steroids 78(6):530-7, 2013.

Simpkins F, Papadia A, Moore K, Kunos C, Michener C, Rose P: Clinical outcome and patterns of recurrence in stage I endometrial adenocarcinoma with lymphovascular space invasion. Int J of Gynecol Cancer SUBMITTED 23(1):98-104, 2013.

Simpkins F, Garcia-Sota, A, Slingerland J: New insights to hormonal therapies for ovarian cancer. Steroids 78(6):530-7, 2013.

Simpkins F, Papadia A, Moore K, Kunos C, Michener C, Rose P: Clinical outcome and patterns of recurrence in stage I endometrial adenocarcinoma with lymphovascular space invasion. Int J of Gynecol Cancer 23(1):98-104, 2013.

Simpkins F, Flores A, Chu C, Berek J, Lucci J, Toso J, Coukos G: Phase I dose escalation study of recombinant human interleukin-18 (SB-485232) administered in combination with pegylated liposomal doxorubicin in recurrent ovarian cancer. J Immunol Rsrch revision submitted 2013.

Simpkins F, Flores A, Chu C, Berek J, Lucci J, Toso J, Coukos G: Phase I, Dose escalation study to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) administered by intravenous infusion in combination with pegylated liposomal doxorubicin (Doxil) in recurrent ovarian cancer. Published as abstract for the ASCO meeting. J Clin Oncol suppl #50659, Jun 2012.

Simpkins F, et al.: Phase I, Dose escalation study to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) administered by intravenous infusion in combination with pegylated liposomal doxorubicin (Doxil) in recurrent ovarian cancer. ASCO. Journal of Clin Oncol, IS THIS PEER OR REVIEW OR ABSTRACT OR ??? Jun 2012.

Simpkins F, et al NEED AUTHORS : Phase I, Dose escalation study to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) administered by intravenous infusion in combination with pegylated liposomal doxorubicin (Doxil) in recurrent ovarian cancer. ASCO Journal of Clin Oncol ABSTRACT presentation OR Original Article? Jun 2012.

Simpkins F, Hevia-Perez P, Sun J, Ullmer W, et al, Slingerland J: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical Cancer Research 18(21):5911-23, 2012.

back to top
Last updated: 07/08/2014
The Trustees of the University of Pennsylvania